ARCT
Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings (ARCT) Q2 2026 earnings
Published Aug 6, 2026
AI summary
- Revenue $2.96M, down 90% from $28.3M a year ago.
- GAAP EPS −$0.84 beat the −$1.03 consensus by $0.19, down from −$0.34 a year ago.
- Arcturus reported second quarter 2026 revenue of $2.96 million, down from $28.3 million in the prior year period.
- The company recorded a net loss of $23.8 million, or $0.84 per share, compared to a $9.2 million loss last year.
- Arcturus regained global rights to its KOSTAIVE vaccine and infectious disease portfolio from CSL Seqirus.
Results vs analyst consensus
Revenue
Reported
$2.96M
Consensus not captured before release
−90% YoY
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$0.84
Consensus −$1.03
Beat by $0.19GAAP EPS: −$0.84
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- Revenue declined significantly due to the termination of the CSL Seqirus collaboration.
- The company reported a wider net loss compared to the same quarter in the previous year.
Read original report
Source: Arcturus Therapeutics Holdings Inc. press release · SEC Form 8-K exhibit 99.1